| I5X Stock | | | EUR 0.83 0.04 4.60% |
Director
Mr. Jeffrey B. Kindler is an Independent Director of Intrexon Corporationrationration. He is the Chief Executive Officer of Centrexion Corporationrationration, a privately held clinical stage biopharmaceutical company a Venture Partner at Lux Capital, a leading VC firm and a managing director at Starboard Capital Partners, a private equity firm. Mr. Kindler was Chief Executive Officer and Chairman of the Board of Pfizer, Inc., a pharmaceutical company, from 2006 until his retirement in December 2010. He joined Pfizer in 2002 as Executive Vice President and General Counsel and assumed positions of increasing responsibility until being named Chief Executive Officer in 2006. Prior to joining Pfizer, he was Chairman of Boston Market Corporation from 2000 to 2001 and President of the Partner Brands group of McDonalds Corporation during 2001. Mr. Kindler also serves as a board member for a number of privately held companies and for several civic, charitable, educational and other organizations. Previously, Mr. Kindler served on the board of Chipotle Mexican Grill, Inc., a chain of Mexican restaurants, from 2012 to 2014 since 2011.
| Age | 63 |
| Tenure | 13 years |
| Phone | 301 556 9900 |
| Web | https://www.precigen.com |
Kindler received a B.A. from Tufts University and a J.D. from Harvard Law School. We believe Mr. Kindler brings leadership, extensive business, operating, legal and policy, and corporate strategy experience to our Board, along with tremendous knowledge of several of the industries in which we operate as well as the fundamentals of our business.
Precigen Management Efficiency
The company has return on total asset
(ROA) of
(0.1219) % which means that it has lost $0.1219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.5132) %, meaning that it generated substantial loss on money invested by shareholders. Precigen's management efficiency ratios could be used to measure how well Precigen manages its routine affairs as well as how well it operates its assets and liabilities.
Precigen has accumulated 182.75
M in total debt with debt to equity ratio
(D/E) of 1.05, which is about average as compared to similar companies. Precigen has a current ratio of 5.6, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Precigen until it has trouble settling it off, either with new capital or with free cash flow. So, Precigen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Precigen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Precigen to invest in growth at high rates of return. When we think about Precigen's use of debt, we should always consider it together with cash and equity.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland. PRECIGEN INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 423 people. Precigen (I5X) is traded on Frankfurt Exchange in Germany and employs 456 people.
Management Performance
Precigen Leadership Team
Elected by the shareholders, the Precigen's board of directors comprises two types of representatives: Precigen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precigen. The board's role is to monitor Precigen's management team and ensure that shareholders' interests are well served. Precigen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precigen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Frank, Independent Director | |
| Jeffrey Kindler, Independent Director | |
| Rob Russell, VP HR | |
| Randal Kirk, Chairman of the Board, Chief Executive Officer | |
| Rick Sterling, Chief Financial Officer | |
| Cesar Alvarez, Independent Director | |
| Donald Lehr, Chief Legal Officer | |
| Vinita Gupta, Independent Director | |
| Rutul Shah, Chief Officer | |
| Jeffrey Perez, Senior Vice President — Intellectual Property Affairs | |
| Randal JD, Ex Chairman | |
| Helen MPH, CEO Pres | |
| Steven Harasym, VP Relations | |
| Fred Hassan, Independent Director | |
| James Turley, Independent Director | |
| Helen Sabzevari, President, Chief Executive Officer, President - Precigen, Inc. | |
| Harry Thomasian, Chief Officer | |
| Marie Rossi, VP Communications | |
| Dean Mitchell, Independent Director | |
| Thomas Reed, Founder, Chief Science Officer | |
| Robert Shapiro, Lead Independent Director | |
Precigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precigen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Precigen Stock
When determining whether Precigen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Precigen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Precigen Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Precigen Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Precigen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Precigen Stock please use our
How to Invest in Precigen guide.
You can also try the
Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Please note, there is a significant difference between Precigen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Precigen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precigen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.